Categories Earnings, Health Care

Zynerba Pharmaceuticals stock soars on receiving US patent for its CBD gel to treat Fragile X syndrome

Cannabinoid therapeutics developer Zynerba Pharmaceuticals (ZYNE) received US patent named “Treatment of Fragile X Syndrome with Cannabidiol”. Shares of Zynerba soared 15% in the pre-market trading hours on Tuesday.

This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the company’s cannabidiol (CBD) product candidate, ZYN002 Transdermal CBD gel.

Zynbera is enrolling FXS patients in the US, Australia and New Zealand for CONNECT-FX study that will evaluate its CBD gel ZYN002. The Devon, Philadelphia-based pharma company expects to report top-line data in the second half of 2019.

Fragile X syndrome (FXS) is a genetic disorder that affects both males and females. As of now, there is no cure for FXS, which causes intellectual disability, behavioral and learning challenges, and developmental delays in children.

About 71,000 US patients are believed to have FXS, based on FXS prevalence estimates of approximately 1 in 3,600 to 4,000 in males and of approximately 1 in 4,000 to 6,000 in females.

The company also expects to announce top-line data results from the other three childhood neuropsychiatric studies in the next two years (one in the third quarter of 2019 and two in the first half of 2020).

Zynerba stock, which ended Monday’s trading session down 1.56% at $5.04, had jumped 70% since the beginning of 2019.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event

 

 

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

4 thoughts on “Zynerba Pharmaceuticals stock soars on receiving US patent for its CBD gel to treat Fragile X syndrome

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top